Publicacións (19) Publicacións de Maria Begoña Taboada Valladares

2023

  1. (Pre)treatment risk factors for late fatigue and fatigue trajectories following radiotherapy for breast cancer

    International Journal of Cancer, Vol. 153, Núm. 9, pp. 1579-1591

  2. Genome-wide association study of treatment-related toxicity two years following radiotherapy for breast cancer

    Radiotherapy and Oncology, Vol. 187

  3. Large-scale meta-genome-wide association study reveals common genetic factors linked to radiation-induced acute toxicities across cancer types

    JNCI Cancer Spectrum, Vol. 7, Núm. 6

  4. Radiation Therapy for Metastatic Lung Cancer: Bone Metastasis and Metastatic Spinal Cord Compression

    Medical Radiology (Springer Science and Business Media Deutschland GmbH), pp. 779-793

  5. Radiogenomics in lung cancer: Where are we?

    Lung Cancer, Vol. 176, pp. 56-74

  6. Reply to: Comments on “(Pre)treatment risk factors for late fatigue and fatigue trajectories following radiotherapy for breast cancer”

    International Journal of Cancer

2022

  1. Development and Optimization of a Machine-Learning Prediction Model for Acute Desquamation After Breast Radiation Therapy in the Multicenter REQUITE Cohort

    Advances in Radiation Oncology, Vol. 7, Núm. 3

  2. The correlation between pre-treatment symptoms, acute and late toxicity and patient-reported health-related quality of life in non-small cell lung cancer patients: Results of the REQUITE study: Symptoms, toxicity and quality of life of lung cancer patients

    Radiotherapy and Oncology, Vol. 176, pp. 127-137

  3. Treatment time and circadian genotype interact to influence radiotherapy side-effects. A prospective European validation study using the REQUITE cohort

    eBioMedicine, Vol. 84

  4. Use of angiotensin converting enzyme inhibitors is associated with reduced risk of late bladder toxicity following radiotherapy for prostate cancer

    Radiotherapy and Oncology, Vol. 168, pp. 75-82

2021

  1. Palliative radiotherapy in CRC

    Foundations of Colorectal Cancer (Elsevier), pp. 429-433

2020

  1. High-dose neoadjuvant chemoradiotherapy versus chemotherapy alone followed by surgery in potentially-resectable stage IIIA-N2 NSCLC. A multi-institutional retrospective study by the Oncologic Group for the Study of Lung Cancer (Spanish Radiation Oncology Society)

    Reports of Practical Oncology and Radiotherapy, Vol. 25, Núm. 3, pp. 447-455

2019

  1. Management of oligometastatic non-small cell lung cancer patients: Current controversies and future directions

    WORLD JOURNAL OF CLINICAL ONCOLOGY, Vol. 10, Núm. 10, pp. 318-339

  2. Prognostic factors in neoadjuvant treatment followed by surgery in stage IIIA-N2 non-small cell lung cancer: a multi-institutional study by the Oncologic Group for the Study of Lung Cancer (Spanish Radiation Oncology Society)

    Clinical and Translational Oncology, Vol. 21, Núm. 6, pp. 735-744

2018

  1. Neoadjuvant treatment followed by surgery versus definitive chemoradiation in stage IIIA-N2 non-small-cell lung cancer: A multi-institutional study by the oncologic group for the study of lung cancer (Spanish Radiation Oncology Society)

    Lung Cancer, Vol. 118, pp. 119-127

  2. Response to: Low level evidence supporting the choice of optimal multimodality treatment approach in patients with stage IIIA NSCLC- ain't no mountain high enough…. to keep me getting to you by Jeremic Branislav

    Lung Cancer

2017

  1. Recent developments in radiotherapy for small-cell lung cancer: a review by the Oncologic Group for the Study of Lung Cancer (Spanish Radiation Oncology Society)

    Clinical and Translational Oncology, Vol. 19, Núm. 10, pp. 1183-1192

  2. Targeted therapy combined with radiotherapy in non-small-cell lung cancer: a review of the Oncologic Group for the Study of Lung Cancer (Spanish Radiation Oncology Society)

    Clinical and Translational Oncology, Vol. 19, Núm. 1, pp. 31-43

2015

  1. Radioterapia neoadyuvante, complementaria e intraoperatoria en el cáncer de recto

    Abordaje multidisciplinar de cáncer colorrectal (Andavira), pp. 315-335